S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Wall Street Futures Dip as Broadcom Slides, Tech Weighed Down Despite Dovish Fed Signals 
Fed Near Neutral Signals Caution Ahead, Shifting Focus to Fixed Income in 2026 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Asian Stocks Slip Ahead of Fed Decision as China Deflation Concerns Deepen 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Indonesia–U.S. Tariff Talks Near Completion as Both Sides Push for Year-End Deal 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
